Literature DB >> 21501423

Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.

Joana M Gil-Mohapel1.   

Abstract

Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an unstable expansion of cytosine-adenine-guanine (CAG) repeats in the HD gene. The symptoms include cognitive dysfunction and severe motor impairment with loss of voluntary movement coordination that is later replaced by bradykinesia and rigidity. The neuropathology is characterized by neuronal loss mainly in the striatum and cortex, and the appearance of neuronal intranuclear inclusions of mutant huntingtin. The mechanisms responsible for neurodegeneration are still not fully understood although excitotoxicity and a consequent increase in intracellular calcium concentration as well as the activation of caspases and calapins are known to play a key role. There is currently no satisfactory treatment or cure for this disease. The YAC128 transgenic mice express the full-length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. As such, these transgenic mice have been an invaluable model not only for the elucidation of the neurodegenerative pathways in HD, but also for the screening and development of new therapeutic approaches. Here, I will review the unique characteristics of this transgenic HD model and will provide a summary of the therapies that have been tested in these mice, namely: potentiation of the protective roles of wild-type huntingtin and mutant huntingtin aggregation, transglutaminase inhibition, inhibition of glutamate- and dopamine-induced toxicity, apoptosis inhibition, use of essential fatty acids, and the novel approach of intrabody gene therapy. The insights obtained from these and future studies will help identify potential candidates for clinical trials and will ultimately contribute to the discovery of a successful treatment for this devastating neurodegenerative disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21501423      PMCID: PMC6493426          DOI: 10.1111/j.1755-5949.2011.00246.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  4 in total

1.  Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.

Authors:  Mali Jiang; Qi Peng; Xia Liu; Jing Jin; Zhipeng Hou; Jiangyang Zhang; Susumu Mori; Christopher A Ross; Keqiang Ye; Wenzhen Duan
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

2.  Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington's Disease Accounts for Some but Not All of the Observed HD-like Motor Deficits.

Authors:  Andrea E Kudwa; Liliana B Menalled; Stephen Oakeshott; Carol Murphy; Richard Mushlin; John Fitzpatrick; Sam F Miller; Kristi McConnell; Russell Port; Justin Torello; David Howland; Sylvie Ramboz; Dani Brunner
Journal:  PLoS Curr       Date:  2013-07-30

Review 3.  Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?

Authors:  Suk-yu Yau; Joana Gil-Mohapel; Brian R Christie; Kwok-fai So
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

4.  Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.

Authors:  Cristine de Paula Nascimento-Castro; Ana Claudia Wink; Victor Silva da Fônseca; Claudia Daniele Bianco; Elisa C Winkelmann-Duarte; Marcelo Farina; Ana Lúcia S Rodrigues; Joana Gil-Mohapel; Andreza Fabro de Bem; Patricia S Brocardo
Journal:  Neural Plast       Date:  2018-08-14       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.